Monopar Therapeutics Inc. MNPR · Stock Open Monopar Therapeutics Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Monopar Therapeutics Inc. Analysis (MNPR)
Is Monopar Therapeutics Inc. a good investment? Monopar Therapeutics Inc. (MNPR) is currently trading at 73.10 USD. Market analysts have a consensus price target of 129.92 USD. This suggests a potential upside from current levels.
Earnings Schedule: Monopar Therapeutics Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -1.92.
Investor FAQ
Does Monopar Therapeutics Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Monopar Therapeutics Inc.?
Monopar Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -2.20.
Company Profile
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 13, 2024 | 1:5 |
Community Discussion